Professional athlete James Graham appointed to strengthen Advisory Board of Impression for the commercial development of IHL-216A

2020-05-20 00:17:33 (AET) by Ring Zhang   1009


Impression Healthcare Limited (ASX: IHL) announces that professional rugby league footballer James Graham has teamed up with the Company’s advisory board to assist with the commercial development of IHL-216A, one of the company’s flagship drug candidates for the treatment of concussion and traumatic brain injury (TBI).

Cannibis drug developer Impression Healthcare Limited (ASX: IHL) announces that professional rugby league footballer James Graham has teamed up with the Company’s advisory board to assist with the commercial development of IHL-216A, one of the company’s flagship drug candidates for the treatment of concussion and traumatic brain injury (TBI).

James Graham is a popular and celebrated premiership playing professional rugby league footballer who plays as a prop for the St. George Illawarra Dragons in the NRL, and England and Great Britain at international level. He is also a regular media commentator and weekly contributor to the TV program, NRL 360 on Fox Sports.

This is the second appointment of a professional athlete for the IHL-216A development program, following the appointment of former professional AFL player Mr Liam Picken announced last in March this year.

James says he is delighted to join the advisory team, as understanding and treating concussion is something he is incredibly passionate about, and Impression and its IHL-216A program has given him a great platform to contribute to the field.

According to the announcement, as part of the Impression team, James Graham has agreed to offer assistant with the following activities:

  1. the development of ‘real world’ aspects of the clinical program for IHL-216A,

  2. to assist in building Impression’s relationship and concussion solutions with the Rugby League Players Association,

  3. to assist with developing an arrangement with the NRL for the use of IHL-216A throughout the elite competition,

  4. to attend Impression meetings with partners, investors, and program participants, and

  5. to work with Impression to further develop its player wellbeing program.

Speaking of the joining of James, CEO and Managing Director of Impression Joel Latham commented that he has been impressed by James’ extensive knowledge of many aspects of traumatic brain injury and considers James as one of the most respected and influential figures in Australian sport.

Impression also has an extensive clinical program being undertaken for 4 cannabinoid clinical assets, focused on areas of medicine with critical unmet need.

Stock Price Chart

text

Please click here to check out the latest IHL share price and announcement.


Source from ASX announcement NRL player James Graham joins Impression TBI program


标签:

声明:这些资讯属于事实信息,仅供参考,不应被视为投资建议或用于投资决策

版权所有,转载需注明出处:61 澳洲财经资讯 news.61financial.com.au

商务合作请联系 support@61financial.com.au


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


推广

cover
宽松货币是硬道理,风险资产攀升节节高

上周金融市场好消息不断,鼓励全球股市大盘继续劲猛涨势。即便是投资风险偏好充斥着金融市场,7月份市场气候可能会受到这样一些因素的影响给市场投资情绪带来打压。

相关文章

cover
Impression成功转型,专攻医用大麻开发领域

Impression Healthcare在本季度内重整并优化其大麻候选药品组合,达成多项里程碑进程,旨在解决全球包括COVID-19相关疾病在内的四大未满足医疗需求,并正式结束其传统牙套业务,集中公司资源专攻大麻领域。